- cafead   Dec 10, 2024 at 11:12: AM
via With a positive phase 3 trial in chronic lymphocytic leukemia (CLL), Eli Lilly hopes to convert Jaypirca’s unique accelerated approval—which allows the BTK inhibitor to be used following another drug in the class—into a full nod.
article source
article source